Primary endocrine therapy (PET), where the cancer is treated solely with an endocrine agent, is an option in women with an ER/PR-positive tumour who are unsuitable or unwilling to undergo surgery (Milla-Santos et al, 2004; Crivellari et al, 2008; Muss et al, 2008). This evidence concerns the gene PGR and neoplasm.